Title
Category
Credits
Event date
Cost
Recorded Presentation from the NCCN Pharmacy Updates: Chemoimmunotherapy Updates in Advanced/Metastatic Non-Small Cell Lung Cancer
  • Lung Cancers
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
This webinar will provide a summary of the newest chemoimmunotherapy options in advanced NSCLC and the toxicities associated with these combination regimens.
Archived NCCN Tumor Boards: Multidisciplinary Management of Head and Neck Cancers
  • Head and Neck Cancers
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
$0.00
Despite advances in radiation therapy (RT) techniques for the treatment of head and neck cancers, patients with head and neck cancers continue to be at risk of oral and dental complications after surgery or RT because of treatment-induced xerostomia and salivary gland dysfunction, which are associated with increased dental caries.
Archived NCCN Tumor Boards: New Approaches to Treatment of Bladder Cancer
  • Bladder Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
$0.00
This activity will help clinicians identify the best treatment options for their patients with bladder cancer.
Recorded Presentation from the NCCN Pharmacy Updates: Maintenance Strategies in the Management of Acute Myeloid Leukemia
  • Acute Myelogenous Leukemia
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Maintenance therapy is an aspect of acute myeloid leukemia (AML) management that currently demonstrates strong promise in efforts to prolong survivability and improve overall survival. Given the forthcoming evidence in this area, it is highly important for health care professionals responsible for the care of patients with AML to be aware of both new treatment standards and emerging research in maintenance therapy options.
Recorded Presentation from the NCCN Pharmacy Updates: Advances in Neoadjuvant Treatment Options in Locally Advanced and Metastatic Rectal Cancer with Deficient Mismatch Repair
  • Rectal Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Treatment options for locally advanced or metastatic rectal cancer are evolving constantly. It is important for care teams to have an understanding of the current treatment approaches, toxicity management, and appropriate supportive care recommendations throughout a patient’s treatment course.
Renal Cell Carcinoma: Evolving Perspectives on Optimal Treatment
  • Kidney Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with renal cell carcinoma (RCC).
Archived NCCN Tumor Boards: Treatment Selection Strategies and Barriers to Clinical Care in Metastatic Breast Cancer
  • Breast Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
$0.00
Clinicians need to understand the diverse and evolving SDOH landscape, especially as it relates to clinical trial access for individuals with metastatic breast cancer (mBC), and they need to consider potential strategies to address SDOH to ensure equitable care and improve overall outcomes for patients with mBC.
Vital Questions for Treatment of Bladder Cancer: Expert Insights on Recent and Near-Future Changes
  • Bladder Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with bladder cancer.
Are You Applying the Latest Guidelines for Multiple Myeloma? Experts Discuss Equitable, Evidence-Based Care
  • Multiple Myeloma
  • 1.50 AAPA Category 1 CME credit
  • 1.50 ABIM Medical Knowledge
  • 1.50 ACPE contact hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
  • 1.50 Participation
$0.00
Join us for this case-based, interactive on-demand program featuring expert perspectives on treatment for patients with newly diagnosed and relapsed/refractory multiple myeloma.
Archived NCCN Tumor Boards: Acute Myeloid Leukemia: The Importance of Individualized Patient Care
  • Acute Myelogenous Leukemia
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
$0.00
Individualized patient care is highly important in acute myeloid leukemia (AML) therapy to ensure the most effective treatment regimens can be selected for appropriate patients.

Pages